Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.
Cesar Michael Samson, MD, MBA
Advertisement
Cesar Michael A. Samson, MD, MBA, is Professor of Ophthalmology and Chief of the Division of Uveitis Services at NYU Grossman School of Medicine, New York, New York.
Articles by Cesar Michael Samson, MD, MBA
At ARVO 2025, in Salt Lake City, Utah, C Michael Samson, MD, MBA, gave insight into his data on immune cell profiling in birdshot retinochoroidopathy using single-cell RNA sequencing.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR Surgical terminates proposed acquisition by Alcon
2
FDA grants Breakthrough Therapy Designation to Oculis’ privosegtor for optic neuritis
3
Rates of retinal layer thinning predict visual field progression in glaucoma
4
International meta-analysis highlights elevated ocular risk in Clade I Monkeypox
5